A Novel Multi-Target Mu/Delta Opioid Receptor Agonist, HAGD, Produced Potent Peripheral Antinociception with Limited Side Effects in Mice and Minimal Impact on Human Sperm Motility In Vitro
Molecules · 2023
DOI: 10.3390/molecules28010427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Fangfang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China, Science and Technology Program of Gansu Province.
Abstract (Originalsprache)
Pain is a common clinical symptom among patients. Although various opioid analgesics have been developed, their side effects hinder their application. This study aimed to develop a novel opioid analgesic, HAGD (H-Tyr-D-AIa-GIy-Phe-NH2), with limited side effects. In vivo studies on mouse models as well as in vitro studies on Chinese hamster ovary (CHO) cells expressing human mu, delta, or kappa opioid receptors (CHOhMOP, CHOhDOP, and CHOhKOP, respectively) and human sperm were conducted. Compared with subcutaneous morphine (10 mg/kg), subcutaneous HAGD (10 mg/kg) produced equipotent or even greater antinociception with a prolonged duration by activating mu/delta opioid receptors in preclinical mouse pain models. The analgesic tolerance, rewarding effects (i.e., conditioned place preference and acute hyperlocomotion), and gastrointestinal transit inhibition of HAGD were significantly reduced compared with those of morphine. Both HAGD and morphine exhibited a withdrawal response and had no impacts on motor coordination. In CHOhMOP and CHOhDOP, HAGD showed specific and efficient intracellular Ca2+ stimulation. HAGD had minimal impact on human sperm motility in vitro, whereas 1 × 10−7 and 1 × 10−8 mol/L of morphine significantly declined sperm motility at 3.5 h. Overall, HAGD may serve as a promising antinociceptive compound.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China.
- Key Laboratory for Reproductive Medicine and Embryo of Gansu, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou 730000, China.
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
ORCID-Profile: Fangfang Li
Förderung
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Science and Technology Program of Gansu Province
- the Science and Technology Project of Lanzhou Science and Technology Bureau
- the Fundamental Research Funds for the Central Universities
Zitieren
APA
Li, F., Yue, F., Zhang, W., Xu, B., Wang, Y., & Zhang, X. (2023). A Novel Multi-Target Mu/Delta Opioid Receptor Agonist, HAGD, Produced Potent Peripheral Antinociception with Limited Side Effects in Mice and Minimal Impact on Human Sperm Motility In Vitro. Molecules. https://doi.org/10.3390/molecules28010427
Vancouver
Li F, Yue F, Zhang W, Xu B, Wang Y, Zhang X. A Novel Multi-Target Mu/Delta Opioid Receptor Agonist, HAGD, Produced Potent Peripheral Antinociception with Limited Side Effects in Mice and Minimal Impact on Human Sperm Motility In Vitro. Molecules. 2023. doi:10.3390/molecules28010427
BibTeX
@article{Li2023,
author = {Li, Fangfang and Yue, Feng and Zhang, Wei and Xu, Biao and Wang, Yiqing and Zhang, Xuehong},
title = {A Novel Multi-Target Mu/Delta Opioid Receptor Agonist, HAGD, Produced Potent Peripheral Antinociception with Limited Side Effects in Mice and Minimal Impact on Human Sperm Motility In Vitro},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28010427}
}
EUVIMED